Introduction {#Sec1}
============

Many cancers are characterized by the overproduction of a range of immunosuppressive cells and cytokines. These not only inhibit the host's antitumor immune response but also thwart attempts to augment anticancer immunity through the use of cancer vaccines. The two best-characterized immunosuppressive cell subsets are FoxP3^+^ T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). The characteristics of both of these cell types have been the subject of comprehensive recent reviews \[[@CR1], [@CR2]\]. MDSCs arise from myeloid progenitor cells that have failed to terminally differentiate into mature granulocytes and macrophages (HLADR^−^ Lin1^low/−^). Granulocytic MDSCs express CD33, CD11b, IL-4Rα, and low levels of CD15 and contain high levels of arginase. Monocytic MDSCs express the same markers but have lower levels of CD15 and also express CD14; in addition to arginase, they also express inducible nitric oxide synthase (iNOS). Naturally occurring CD4^+^ Tregs are characterized by the expression of the IL-2 receptor α-chain (CD25). These cells naturally arise in the thymus, and after differentiation, the naive CD4^+^ CD25^+^ CD45RA^+^ T cells are exported to the periphery \[[@CR3]--[@CR5]\]. Intracellular expression of the forkhead box protein 3 transcription factor (FoxP3) and low expression of the IL-7 receptor, CD127, are further characteristics of suppressive Tregs \[[@CR1], [@CR6]\].

While there are published data on circulating Treg levels in pancreatic cancer \[[@CR7]\], including comprehensive clinicopathological correlations, there is little published data investigating MDSCs specifically in pancreatic cancer, or indeed in esophageal and gastric cancer. Patients with metastatic pancreatic cancer were included in an early paper characterizing granulocytic MDSCs in cancer patients with diverse primary tumors \[[@CR8]\]. In another series of over 100 patients, which included patients with pancreatic cancer, a significant increase in circulating HLADR^−^ Lin1^low/−^ CD33^+^ CD11b^+^ MDSCs was demonstrated in cancer patients relative to controls: Increasing numbers of MDSCs correlated with increasing stage of disease and patient-derived MDSCs impaired T-cell proliferation \[[@CR9]\].

Although elevated MDSC numbers have been reported in single tumor site series, MDSC levels, their phenotype, and their functional effects may vary from cancer to cancer. We present for the first time a comprehensive clinicopathological correlation of circulating MDSCs and Tregs in pancreatic, esophageal and gastric cancer patients, together with an assessment of the functional significance of these changes by analysis of systemic arginase I levels. We demonstrate that MDSC levels are an independent prognostic factor for survival. We have evaluated the cytokine profiles in these patients with particular reference to IL-13 levels.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Twenty to thirty milliliters of venous blood was collected from pancreatic and esophago-gastric cancer patients (*N* = 131) and age-/sex-matched normal healthy controls (*N* = 54). Subjects were recruited between July 2008 and April 2010. Cancer patients were recruited from oncology clinics at St Luke's Cancer Center, Surrey, UK, and all had histologically confirmed pancreatic or esophago-gastric cancer. Age- and sex-matched healthy controls were recruited from surgical minor operation clinics at the Royal Surrey County Hospital. No subject had a history of autoimmune disease or of recent steroid therapy, and no control donor had a prior history of cancer. All subjects provided written informed consent and the study was approved by the local ethics committee. Blood was drawn into li-heparin tubes (BD Biosciences, Europe), and following centrifugation, the plasma was removed and peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Hypaque gradients. Plasma samples were stored at −80°C, and PBMC were counted, frozen at −80°C, and stored in liquid *N*~*2*~ for subsequent batch analysis.

Cancer patients were subdivided into three groups according to the site of their primary tumor: (1) pancreatic (*N* = 46), (2) esophageal, esophago-gastric junction or cardia (primary tumor arising ≤5 cm below the esophago-gastric junction) (*N* = 60), and (3) non-cardia gastric cancer patients (primary tumor arising in gastric body, fundus, or antrum) (*N* = 25). The following clinicopathological characteristics were recorded: age, sex, WHO performance status (PS), histological grade, AJCC stage (2010), prior weight loss, smoking status at time of sample collection, and whether patients received subsequent systemic treatment following immune testing.

Immunophenotypic analysis of cells {#Sec4}
----------------------------------

PBMC were recovered and washed in 0.15 M phosphate-buffered saline, Dulbecco's A (Oxoid, UK). Cells were aliquoted for T-cell subset, Treg and MDSC analysis. The LIVE/DEAD Cell Stain Kit (Invitrogen, UK) was used to differentiate viable and dead cells. After washing in binding buffer (BD Biosciences, Europe), the following anti-human monoclonal antibodies were used for flow cytometry: anti-CD3-FITC, anti-CD4-PE Cy7, anti-CD8-PE Cy5, anti-CD25-APC Cy7, anti-CD127-PE, anti-HLADR-APC Cy7, anti-Lin1(CD3,14,16,19,20,56)-FITC, anti-CD33-PE Cy5 and anti-CD11b-PE Cy7 (BD Biosciences, Europe). For Treg intra-nuclear FoxP3 anaylsis, permeabilization and staining for FoxP3 and an isotype control was performed for each donor using the eBioscience anti-FoxP3 staining set, according to the manufacturer's instructions. Cells were washed in binding buffer and analyzed using a MACSQuant flow cytometer with MACSQuantify software (Miltenyi Biotec). For T-cell subset and Treg analysis, the acquisition and analysis gates were restricted to the live lymphocyte population, whereas for MDSC analysis, all live cells were included. CD3^+^ CD4^+^ and CD3^+^ CD8^+^ cells were calculated as a percentage of live CD3^+^ lymphocytes. Tregs were identified as CD4^+^ CD25^+^ CD127^low/−^ FoxP3^+^ and calculated as a percentage of live CD4^+^ lymphocytes. Finally, HLADR^−^ Lin1^low/−^ CD33^+^ CD11b^+^ MDSCs were calculated as a percentage of total live PBMC.

Arginase I ELISA {#Sec5}
----------------

Plasma arginase I levels in cancer patients (*N* = 119) and controls (*N* = 31) were analyzed using an enzyme-linked immunosorbent assay specific for human arginase I (liver type) using a commercially available kit (BioVendor, UK). Hemolyzed samples were excluded. Samples were assayed in duplicate and the mean absorbance was calculated from the standard curve.

Bio-plex cytokine assay {#Sec6}
-----------------------

Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels in cancer patients (*N* = 119) and controls (*N* = 33) were analyzed using the Bio-Plex human cytokine assay (Bio-Rad, UK), using Bio-Plex software. Hemolyzed samples were excluded and samples were assayed in duplicate.

Interleukin-13 ELISA {#Sec7}
--------------------

For validation of IL-13 levels, plasma IL-13 levels in pancreatic cancer patients (*N* = 24) and controls (*N* = 18) were analyzed using an enzyme-linked immunosorbent assay specific for human IL-13 using a commercially available kit (Thermo Scientific, UK). Hemolyzed samples were excluded. Samples were assayed in duplicate and the mean absorbance was calculated from the standard curve.

Statistical analysis {#Sec8}
--------------------

Clinicopathological variables included age, diagnosis, WHO performance status, tumor grade, AJCC 2010 stage, weight loss, smoking status at time of sample collection, prior treatment status and whether patients received any systemic therapy following sample donation. Continuous variables were summarized as medians and ranges. Median levels of MDSC, Treg, arginase I and cytokines were compared in pancreatic, esophageal and gastric cancer patients versus controls using the nonparametric two-sample Wilcoxon rank sum test and applying a Bonferroni correction to control for multiple testing (statistical significance adjusted to *P* \< 0.0125). The association between two continuous factors was investigated calculating the Spearman's correlation coefficient.

Independent factors significantly associated with survival were identified using log-rank (LR) analysis for categorical variables and univariate Cox proportional hazards models for continuous variables (Wald test statistic), including consideration of transformations for nonlinear relationships with hazard. MDSC level was analyzed as a continuous covariate and required no transformation. All variables significant at the 10% level on univariate analysis were considered further in the multivariate setting. Multivariate Cox proportional hazards models were derived using backward elimination variable selection based on a 10% level of significance, including subsequent systemic therapy in all models in view of its clinical relevance. Adjusted hazard ratios for each significant independent factor are presented. Plots of survival estimates are presented using the method of Kaplan and Meier.

Results {#Sec9}
=======

Patients {#Sec10}
--------

We analyzed peripheral blood mononuclear cells and cytokine profiles of 46 patients with pancreatic cancer, 60 with esophageal cancer, 25 with gastric cancer and 54 age-/sex-matched controls. The patient characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristicsVariableCategoryPancreas *N* = 46Esophagus *N* = 60Gastric *N* = 25UGI cancer *N* = 131WHO performance status0/128 (60.9%)39 (65.0%)16 (64.0%)83 (63.4%)212 (26.1%)16 (26.7%)6 (24.0%)34 (26.0%)35 (10.9%)4 (6.7%)3 (12.0%)12 (9.2%)Unknown1 (2.2%)1 (1.7%)0 (0.0%)2 (1.5%)Tumor grade12 (4.3%)1 (1.7%)0 (0.0%)3 (2.3%)212 (26.1%)18 (30.0%)6 (24.0%)36 (27.5%)316 (34.8%)40 (66.7%)17 (68.0%)73 (55.7%)Not assessable^a^16 (34.8%)1 (1.7%)2 (8.0%)19 (14.5%)AJCC stage 2010II/III11 (23.9%)25 (41.7%)8 (32.0%)44 (33.6%)IV33 (71.7%)34 (56.7%)17 (68.0%)84 (64.1%)Not assessable^b^2 (4.3%)1 (1.7%)0 (0.0%)3 (2.3%)Weight lossNone17 (37.0%)21 (35.0%)5 (20.0%)43 (32.8%)≤10%12 (26.1%)20 (33.3%)4 (16.0%)36 (27.5%)\>10%16 (34.8%)17 (28.3%)14 (56.0%)47 (35.9%)Unknown1 (2.2%)2 (3.3%)2 (8.0%)5 (3.8%)Smoking statusCurrent7 (15.2%)12 (20.0%)5 (20.0%)24 (18.3%)Ex ≤ 12 months2 (4.3%)3 (5.0%)1 (4.0%)6 (4.6%)Ex \> 12 months17 (37.0%)18 (30.0%)10 (40.0%)45 (34.4%)Never15 (32.6%)22 (36.7%)6 (24.0%)43 (32.8%)Unknown5 (10.9%)5 (8.3%)3 (12.0%)13 (9.9%)Prior treatment statusNone32 (69.6%)38 (63.3%)19 (76.0%)89 (67.9%)Adjuvant/Neoadjuvant chemotherapy3 (6.5%)7 (11.7%)1 (4.0%)11 (8.4%)Palliative chemotherapy11 (23.9%)15 (25.0%)5 (20.0%)31 (23.7%)Subsequent treatment statusNone6 (13.0%)13 (21.7%)6 (24.0%)25 (19.1%)Chemotherapy21 (45.7%)28 (46.7%)19 (76.0%)68 (51.9%)Chemoradiation0 (0.0%)8 (13.3%)0 (0.0%)8 (6.1%)Biological agent0 (0.0%)1 (1.7%)0 (0.0%)1 (0.8%)Chemotherapy and biological agent19 (41.3%)7 (11.7%)0 (0.0%)26 (19.8%)Randomized controlled trial0 (0.0%)3 (5.0%)0 (0.0%)3 (2.3%)Survival statusAlive9 (19.6%)23 (38.3%)8 (32.0%)40 (30.5%)Dead37 (80.4%)37 (61.7%)17 (68.0%)91 (69.5%)Unknown0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)^a^Tumor grade not assessable due to insufficient tissue (e.g., fine-needle aspirate, cytological diagnosis)^b^Stage not assessable with tumor recurrence following prior resection

Following blood donation, the majority of patients subsequently received systemic therapy (80.9%). Twenty-one patients in the pancreatic cohort received standard gemcitabine-based chemotherapy and 19 received gemcitabine and capecitabine chemotherapy in combination with either concomitant or sequential treatment with the anti-telomerase class II peptide vaccine, GV1001. The 7 esophageal cancer patients who went on to receive chemotherapy and a biological agent all received standard chemotherapy followed by treatment with an experimental agent upon progression. The 3 esophageal cancer patients who were subsequently treated in the context of a randomized control trial received chemotherapy in combination with an EGFR monoclonal antibody or placebo (treatment blinded). Of the minority of upper GI patients who had received treatment prior to immune testing (32.1%), 11 had received neoadjuvant or adjuvant chemotherapy prior to relapse and 31 had received prior palliative chemotherapy. None of these patients had received therapy within 8 weeks prior to blood donation, and all had progressed at the time of immune testing.

MDSCs are elevated in pancreatic, gastric and esophageal cancer and are associated with elevations of arginase I and Tregs {#Sec11}
--------------------------------------------------------------------------------------------------------------------------

MDSC percentages were statistically significantly elevated in pancreatic, esophageal and gastric cancer, when compared with controls (Fig. [1](#Fig1){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}), with median (range) percentages of 2.1 (0.2--11.2): *P* \< 0.001, 1.3 (0.4--6.0): *P* \< 0.001, 1.5 (0.2--10.0): *P* = 0.002, and controls 0.8 (0.1, 2.0), respectively. There was no significant difference in MDSC percentage in the group of patients who had received any chemotherapy prior to immune testing and those who had not (*P* = 0.61).Fig. 1MDSC and Treg FACS and scatter plots of cancer patients and healthy controls. **a** live HLADR^−^ Lin1^low/−^ CD33^+^ CD11b^+^ MDSC FACS gating of PBMC of a pancreatic cancer patient (*above*) and a healthy control (*below*). P1, the ViViD low population represents viable cells with reduced amine staining, P2 represents the HLADR negative, lineage low/negative population and UR3, live HLADR^−^ Lin1^low/−^ CD33^+^ CD11b^+^ cells, calculated as a percentage of live cells in P1. **b** live CD4^+^ CD25^+^ CD127^low/−^ FoxP3^+^ Treg FACS gating of PBMC of the same pancreatic cancer patient (*above*) and healthy control (*below*). P1, the lymphocyte population. P2, viable lymphocytes. P4, CD4^+^ population. P5, CD25^+^ CD127^low/−^. Histograms represent the FoxP3^+^ Treg population (FITC^+^, right) and the FoxP3^−^ non-Treg population. Tregs are calculated as a percentage of live CD4^+^ lymphocytes. **c** scatter plot of MDSC % in controls and cancer patients. Bar denotes median in each group. \*, statistically significant difference from healthy controls. **d** scatter plot of Treg % in controls and cancer patientsTable 2MDSC, Treg and arginase I levelsNumber patients median (range) *P* valueControl *N* = 54Pancreas *N* = 46Esophagus *N* = 60Gastric *N* = 25UGI cancer *N* = 125MDSC (%)*N* = 47*N* = 44*N* = 56*N* = 23*N* = 1230.8 (0.1, 2.0)2.1 (0.2, 11.2)1.3 (0.4, 6.0)1.5 (0.2, 10.0)1.4 (0.2, 11.2)*P* \< 0.001*P* \< 0.001*P* = 0.002*P* \< 0.001Treg (%)*N* = 46*N* = 40*N* = 51*N* = 17*N* = 1083.6 (0.6, 14.3)7.5 (2.3, 20.6)6.5 (1.0, 22.2)7.8 (3.2, 20.2)7.0 (1.0, 22.2)*P* \< 0.001*P* \< 0.001*P* = 0.002*P* \< 0.001Arginase I conc. (ng/ml)*N* = 31*N* = 44*N* = 53*N* = 22*N* = 1197.7 (5.0, 97.4)16.7 (5.1, 293.0)19.9 (5.1, 167.8)36.5 (9.2, 195.0)22.0 (5.1, 293.0)*P* = 0.020 (ns)*P* \< 0.001*P* \< 0.001*P* \< 0.001Number of patients (*N*), median (range), Wilcoxon rank sum test *P* value of cancer group versus control. The UGI (upper gastrointestinal) cancer group consists of the pancreatic, esophageal and gastric cancer patients combined. Bonferonni correction applied due to multiple testing with the control arm, statistical significance adjusted to *P* \< 0.0125

Arginase I was elevated in all three diseases, and this achieved statistical significance in esophageal and gastric cancer when using a Bonferroni correction for multiple testing. There was a strong trend toward increasing arginase I level in pancreatic cancer, which did not reach statistical significance (*P* = 0.020). Treg levels were also statistically significantly elevated in all three diseases compared with controls (*P* ≤ 0.002), and there was a positive correlation between MDSC and Treg percentages with a Spearman's rank correlation of 0.43. There was no correlation between MDSC and CD4 or CD8 percentages (data not shown). The majority of patients in the study had stage IV disease (64.1%) and grade 3 tumors (55.7%). As only 44 patients (33.6%) had stage II--III disease, such patients were combined for analysis. In our dataset, there was no evidence of increasing MDSC percentage or of arginase I concentration with stage (*P* = 0.51 and *P* = 0.53, respectively). However, there was a tendency for patients harboring high-grade tumors to have higher arginase levels compared with grade 1/2 tumors (*P* = 0.044). There was no significant effect of grade on MDSC% (*P* = 0.61).

Cytokine profiling of pancreatic, esophageal and gastric cancer shows Th2 skewing and significant elevations of the Th2 cytokine IL-13 (Table [3](#Tab3){ref-type="table"}) {#Sec12}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows cytokine levels for IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF. IL-5, IL-6 and IL10 levels were all statistically significantly elevated in patients' plasma, compared with controls (*P* ≤ 0.004). We analyzed IL-13 levels by Bio-Plex assay for all three cancers and demonstrated statistically significant increases in IL-13 in all three diseases compared with controls (*P* \< 0.001). We confirmed the elevated IL-13 levels in pancreatic cancer patients versus controls using a separate ELISA (Thermo Scientific, UK) and confirmed a statistically significant increase in IL-13 (*P* \< 0.001). As expected, there was also a highly statistically significant elevation of VEGF in cancer patients. There was a positive correlation between MDSC levels and IL-13 with a Spearman's rank correlation of 0.32.Table 3Bio-plex assay of plasma cytokines in controls and cancer patientsNumber patients median (range) *P* valueControl *N* = 33Pancreas *N* = 43Esophagus *N* = 52Gastric *N* = 24UGI cancer *N* = 119IL-221.1\
(0, 4434.9)90.7\
(0, 6254.2)\
*P* = 0.3870.6\
(0, 6085.6)\
*P* = 0.1682.6\
(0, 2543.0)\
*P* = 0.2681.6\
(0, 6254.2)\
*P* = 0.17IL-41.2\
(0, 47.4)0\
(0, 190.5)\
*P* = 0.870\
(0, 32.8)\
*P* = 0.020 (ns)8.7\
(0, 123.2)\
*P* = 0.00610\
(0, 190.5)\
*P* = 0.84IL-50\
(0, 117.0)7.4\
(0, 883.2)\
*P* = 0.00410.6\
(0, 96.8)\
*P* \< 0.00110.2\
(2.7, 242.2)\
*P* \< 0.0019.6\
(0, 883.2)\
*P* \< 0.001IL-686.3\
(8.6, 2038.3)211.3\
(30.7, 9352.1)\
*P* \< 0.001184.1\
(24.7, 4606.9)\
*P* \< 0.001234.0\
(13.5, 3009.3)\
*P* = 0.0029197.6\
(13.5, 9352.1)\
*P* \< 0.001IL-1016.8\
(0, 214.5)39.7\
(0.3, 918.7)\
*P* \< 0.00138.0\
(0, 668.7)\
*P* \< 0.00163.8\
(5.7, 433.0)\
*P* \< 0.00142.9\
(0.3, 918.7)\
*P* \< 0.001IL-12 (p70)135.4\
(0, 651.4)149.9\
(0, 12714.9)\
*P* = 0.41208.5\
(0, 9696.6)\
*P* = 0.074363.3\
(0, 6967.5)\
*P* = 0.0026201.6\
(0, 12714.9)\
*P* = 0.038 (ns)IL-1327.5\
(0, 148.5)112.6\
(0, 2140.0)\
*P* \< 0.00174.9\
(7.6, 742.6)\
*P* \< 0.00184.4\
(7.6, 715.2)\
*P* \< 0.00187.0\
(0, 2140.0)\
*P* \< 0.001IL-170\
(0, 341.8)0\
(0, 143.8)\
*P* = 0.310\
(0, 427.3)\
*P* = 0.560\
(0, 460.5)\
*P* = 0.370\
(0, 460.5)\
*P* = 0.36GCSF51.6\
(0, 235.9)52.6\
(0, 328.9)\
*P* = 0.9219.8\
(0, 249.9)\
*P* = 0.021 (ns)53.6\
(2.6, 153.0)\
*P* = 0.5839.7\
(0, 328.9)\
*P* = 0.35IFN-γ^a^876.7\
(0, 25060.4)192.6\
(0, 10926923.8)\
*P* = 0.11890.8\
(0, 26288.0)\
*P* = 0.511311.6\
(0, 128613.3)\
*P* = 0.25725.8\
(0, 10926923.8)\
*P* = 0.48TNF-α^a^29.0\
(0, 1422.5)36.7\
(0, 16113.4)\
*P* = 0.670\
(0, 2167.3)\
*P* = 0.046 (ns)50.9\
(0, 3730.7)\
*P* = 0.3327.3\
(0, 16113.4)\
*P* = 0.61VEGF^a^798.5\
(214.7, 4378.3)1232.1\
(0, 6957.3)\
*P* = 0.0682120.2\
(160.8, 14459.6)\
*P* \< 0.0012322.7\
(315.7, 11915.6)\
*P* \< 0.0011711.1\
(0, 14459.6)\
*P* \< 0.001Number of patients (*N*), median, (Range), Wilcoxon rank sum test *P* value of cancer group versus control. The UGI (upper gastrointestinal) cancer group consists of the pancreatic, esophageal and gastric cancer patients combined. Bonferonni correction applied due to multiple testing with the control arm, statistical significance adjusted to *P* \< 0.0125^a^Logarithmic transformations applied

MDSC levels are an independent prognostic factor in pancreatic, esophageal and gastric cancer (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) {#Sec13}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ninety-one (69%) of the 131 cancer patients had died at the time of analysis. Median follow-up of the 40 alive patients was 8.3 months (inter-quartile range: 4.1--13.5), similar across diagnostic groups. Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show the univariate analysis of survival. As was expected, performance status ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \chi^{2}_{\text{Log - Rank}} $$\end{document}$ = 7.7, *P* = 0.022) were statistically significantly associated with outcome. Median survival for patients with pancreatic cancer (5.0 months, 95% CI: 3.4, 7.3) was worse than that for gastric (5.9 months, 95% CI: 4.0, 10.6) and esophageal cancer (9.3 months, 95% CI: 7.2, 12.6). MDSC level was significantly associated with survival ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \chi^{2}_{\text{Wald}} $$\end{document}$ = 21.3, *P* \< 0.001), Table [5](#Tab5){ref-type="table"}. Treg percentage, however, was not. There was no evidence that tumor grade, smoking status, prior or subsequent treatment status had an impact on survival in this dataset.Table 4Univariate survival--categorical measurements*N*DeathsMedian S(t) (95% CI)6-mo S(t) (%)12-m S(t) (%)Log-rank, *P* valueOverall131916.9 (5.3, 9.1)53.428.0--Diagnosis Pancreas46375.0 (3.4, 7.3)41.114.910.2, *P* = 0.006 Esophagus60379.3 (7.2, 12.6)65.639.8 Gastric25175.9 (4.0, 10.6)46.925.0WHO performance status 0/183519.1 (6.9, 10.7)64.634.228.7, *P* \< 0.001 234285.1 (3.9, 8.5)41.320.6 312112.4 (1.0, 4.8)11.10Tumor grade1/239256.9 (5.4, 12.1)58.636.90.54, *P* = 0.46 373547.2 (4.8, 9.2)52.826.7AJCC stage 2010 II/III442510.1 (6.3, 12.6)65.040.66.9, *P* = 0.008 IV84645.4 (4.2, 7.3)46.621.7Weight loss None43269.4 (6.9, 12.3)67.841.17.7, *P* = 0.022 ≤10%36288.5 (5.3, 10.2)61.225.9 \>10%47344.8 (3.7, 6.9)36.319.2Smoking status Current24175.7 (2.7, 9.3)49.426.30.75, *P* = 0.69 Ex-smoker51358.1 (5.1, 11.2)60.132.1 Never43307.2 (5.1, 10.1)55.625.1Prior treatment No89596.9 (5.1, 9.2)55.327.10.2, *P* = 0.68 Yes42325.4 (3.6, 9.4)49.329.0Subsequent treatment No25205.4 (2.2, 10.1)45.921.01.3, *P* = 0.25 Yes106717.2 (5.4, 9.1)55.029.6MDSC ≤2.0%80489.3 (6.3, 12.1)63.239.016.1, *P* \< 0.001 \>2.0%43384.6 (2.2, 6.0)36.610.4*S*(*t*) survivalFig. 2**a** Overall survival for MDSC % above and within normal limits. There was a significant difference between cancer patients' survival in those with a normal MDSC% (as defined by the range seen in healthy controls, ≤2.00%) and those with an elevated MDSC% (\>2.00%): ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \chi^{2}_{\text{Log - Rank}} $$\end{document}$ = 16.1, *P* \< 0.001). **b** Log (hazard) plot with increasing MDSC %. A unit increase in MDSC percentage was associated with an increased risk of death (hazard ratio = 1.22, 95% CI: 1.06, 1.41)Table 5Univariate survival--continuous measurementsVariable*N*Transformation^a^Wald χ^2^*P* valueAge131NA0.040.84Treg (%)108NA1.50.22Arginase 1119NA1.90.17MDSC (%)123Linear21.3\<0.001*NA* not applicable^a^Nonlinear transformations considered

No control sample had an MDSC percentage of greater than 2.0% of their total live PBMC (*N* = 47). Patients were dichotomized into those with above normal range of MDSC percentage (MDSCs \> 2.0%) and those with an MDSC level in the normal range (MDSCs ≤ 2.0%). Forty-three patients with elevated MDSCs had an inferior survival, with a median survival of 4.6 months (95% CI: 2.2, 6.0) and 12-month survival of 10.4% compared with 80 patients with normal MDSCs, median survival of 9.3 months (95% CI: 6.3, 12.1) and 12-month survival of 39% (Fig. [2](#Fig2){ref-type="fig"}a).

A multivariable model for overall survival was based on 115 patients (82 deaths), considering all variables significant in the univariate analysis with *P* \< 0.1. The final model included subsequent chemotherapy and selected diagnostic group ($\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \chi^{2}_{\text{Wald}} $$\end{document}$ = 6.7, *P* = 0.036), AJCC stage ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \chi^{2}_{\text{Wald}} $$\end{document}$ = 3.3, *P* = 0.071), performance status ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \chi^{2}_{\text{Wald}} $$\end{document}$ = 7.3, *P* = 0.007) as significant prognostic factors of survival (Table [6](#Tab6){ref-type="table"}). Although weight loss was significant in the univariate analysis, it was not significant in the multivariate setting and therefore was not included in the final analysis. MDSC level retained statistical significance in the multivariable model when adjusted by the effects of other prognostic factors. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio of 1.22 (95% CI: 1.06--1.41), Fig. [2](#Fig2){ref-type="fig"}b.Table 6Backward elimination multivariable model for overall survivalVariableLevelsWald χ^2^*P* valueHR (95% CI)DiagnosisEsophagus6.70.0361.0Gastric1.84 (0.96, 3.52)Pancreas1.84 (1.11, 3.05)WHO performance status0,116.2\<0.0011.022.09 (1.26, 3.47)33.95 (1.85, 8.44)AJCC stage 2010II, III3.30.0711.0IV1.60 (0.96, 2.68)Subsequent treatmentNo0.010.931.0Yes0.97 (0.56, 1.70)MDSCLinear7.30.0071.22 (1.06, 1.41)^a^*N* = 115 patients (82 deaths) with complete information^a^Increased hazard of death based on a unit increase in MDSC

Discussion {#Sec14}
==========

The efficacy of cancer vaccines and other immunotherapies will be improved by addressing the immunosuppressive factors associated with malignancy, both systemically and in the local tumor microenvironment. In this comprehensive analysis of some of these factors, we have shown a statistically significant increase in circulating MDSC numbers in patients with pancreatic, esophageal and gastric cancer compared with age- and sex-matched controls. MDSCs exert their immunosuppressive activity through multiple mechanisms, one of these being through arginine depletion. MDSCs express high levels of arginase: Arginase hydrolyzes the amino acid [l]{.smallcaps}-arginine to ornithine and urea. There are two isoforms of arginase, cytoplasmic arginase I and mitochondrial arginase II, encoded by two different genes. MDSC expressing arginase I deplete [l]{.smallcaps}-arginine from the microenvironment and profoundly inhibit T-cell function \[[@CR10], [@CR11]\]. Inhibition of arginase I restores T-cell function in vitro and induces an antitumor response in vivo \[[@CR11]\]. Previously, increased numbers of MDSCs in the peripheral blood of renal cancer patients correlated with low [l]{.smallcaps}-arginine and high ornithine levels in plasma, and a profound T-cell dysfunction \[[@CR12]\]. In this study, we have demonstrated elevations of plasma arginase I compared with controls in all three cancer types, and this difference achieved levels of statistical significance in esophageal and gastric cancer.

MDSCs may exert their immunosuppressive effects partially through the induction of Tregs as reported in hepatocellular carcinoma \[[@CR13]\]. Sunitinib caused a significant reduction in MDSC numbers in patients with renal cell carcinoma and the change in T regulatory cells tracked those of MDSC numbers with a significant correlation between the two \[[@CR14]\]. We found a significant increase in Tregs in pancreatic, esophageal and gastric cancer compared with controls and a positive correlation between MDSC and Treg percentage with a Spearman's correlation of 0.43. These data complement previously published data on FoxP3^+^ Tregs in pancreatic cancer, in which a direct correlation between high levels of Tregs within the tumoral lymphocytic infiltrate and the presence of distant metastasis and high tumor stage and grade was demonstrated \[[@CR7]\]. In a multivariate model adjusting for other clinical and pathological variables, they found that the prevalence of Tregs in the CD4^+^ T-cell population was an independent prognostic factor. The study did not directly ascertain circulating Treg numbers in the blood of these patients.

A unique and important finding of our study is that MDSC numbers are an independent prognostic factor in patients with pancreatic and esophago-gastric cancer. We constructed a multivariable model in 115 patients for overall survival including key variables of diagnosis, performance status, stage and the use of systemic therapy following immune assessment. MDSCs remained an independent prognostic factor significantly related to survival, with a unit increase in MDSCs being associated with a 22% increased risk of death (hazard ratio of 1.22, 95% CI 1.06--1.41). Should these findings be independently validated, MDSC percentage could become a parameter for routine use in the prognostic modeling of these diseases. Although we have not shown an association with MDSC and stage (as was demonstrated in the work of Diaz-Montero and colleagues \[[@CR9]\]), our study specifically reports on only 3 tumor sites. Their work included 17 different cancers, nearly half of which were breast cancer patients. It may be that some cancers are associated with profound immunosuppression even at an early stage while other cancers may only generate severe systemic immunosuppression when metastatic. This underlies the importance of reporting immune status data separately for each primary cancer type.

Bellone and colleagues first reported an increase in IL-10 and TGF-β concentrations in the sera of pancreatic cancer patients and showed that the anti-proliferative activity of pancreatic carcinoma-conditioned medium on PBMCs was accounted for mainly by the combined action of IL-10 and TGF-β \[[@CR15]\]. There was an increase in IL-4 production and decrease in interferon-γ and IL-12 production from stimulated PBMCs, thus demonstrating a skewing of T-cell cytokine production toward a Th2 immunophenotype. We confirm this Th2 skewing in pancreatic cancer and extend these observations to esophageal and gastric cancer, demonstrating statistically significant increases in the plasma concentrations of the Th2 cytokines IL-5, IL-6 and IL-10 in these patients compared with controls. The elevation of IL-6 is intriguing in view of recent data showing that the combination of IL-6 and GM-CSF was the most potent generator of MDSC-like suppressor cells from normal donor PBMCs, compared with all other combinations tested \[[@CR16]\]. This adds to other reports of IL-6 as a significant inducer of MDSCs \[[@CR17]\].

A particularly important finding of our study is that in patients with pancreatic, esophageal and gastric cancer, there is a significant elevation of plasma IL-13. This was initially demonstrated using the Bio-Plex assay. Other groups have demonstrated significant elevations of IL-13 in other solid tumors, for example, melanoma, using the multiplex Luminex assay \[[@CR18]\]. Our data contrast with that of another more recent study by Bellone and colleagues, who examined a large series of cytokines in patients with pancreatic cancer \[[@CR19]\]. They again detected elevated levels of IL-10 and TGF-β but found that IL-13 levels were lower in patients than in controls. We could not re-run the IL-13 assay used in their study (Euroclone ELISA) as it is no longer commercially available, but instead used a separate ELISA assay (Thermo Scientific) to validate our results in the pancreatic cohort and confirmed a significant elevation of serum IL-13 in patients relative to controls. Our data are not the first to contradict some of the IL-13 findings in the Bellone study. Formentini and colleagues demonstrated the presence of messenger RNA transcript for IL-13 in 6/6 pancreatic cancer cell lines \[[@CR20]\]. There was detectable IL-13 protein in the conditioned media of all of these cell lines by ELISA. The IL-13 concentration in the MiaPaCa2 media was \>300 pg/ml. In contrast, Bellone demonstrated minimal IL-13 expression and critically a complete absence of IL-13 in the supernatants of pancreatic cancer cell lines using the same ELISA used to assay serum in their study. This included cell lines also tested by Formentini.

An elevation of IL-13 in pancreatic cancer is a biologically plausible finding. Formentini's study demonstrated an absence of IL-13 in normal pancreatic cells but found high IL-13 in ductal cancer cells and evidence of IL-4R immunoreactivity in 40 and 43% of pancreatic cancers, respectively, (IL-13 binds a complex of the IL-13 receptor α1 chain (IL-13Rα1) and the IL-4 receptor α chain (IL-4Rα)). High IL-13 was associated with lymph node involvement and outcome, with no patient with high expression surviving more than three years following curative resection. They presented evidence demonstrating that IL-13 is an autocrine growth factor in the disease. In some pancreatic cancer cell lines, IL-13 caused a dose-dependent increase in growth, mediated by p44/42 MAPK signaling, which could be inhibited in a dose-dependent manner by IL-13-neutralizing antibodies.

The finding of a positive correlation between IL-13 levels and MDSC numbers in our study lends yet more biological plausibility to the demonstration and importance of elevated IL-13 in these diseases, given that IL-13 also appears to be pivotal for the full immunosuppressive functionality of MDSCs. Tumor-induced CD11b^+^ splenocytes can be sorted by the presence of the IL-4Rα \[[@CR21]\]. The IL-4Rα-positive cells are monocytoid, produce significant amounts of IL-13 and IFN-γ, and are suppressive. The receptor negative cells, which are polymorphonuclear-like, do not constitutively secrete these cytokines and are non-suppressive. The presence of the receptor is essential for suppressor function: IL-4Rα is not subserving IL-4-mediated signaling as CD11b^+^ cells from IL-4 knockout mice still suppress T-cell function. Full functionality of tumor-conditioned murine MDSCs requires the coordinated effect of both IL-13 and IFNα, released by the cells in an autocrine fashion, and results in the dual expression of arginase and nitric oxide synthase II. In cancer patients, there is a significant correlation between percentage IL4Rα^+^ CD14^+^ cells and suppressive activity \[[@CR22]\].

Highfill and colleagues have shown that MDSCs cultured in IL-13 are significantly more suppressive in an allogeneic mixed leukocyte reaction than MDSCs cultured without IL-13 \[[@CR23]\]. This suppressive effect is directly mediated via arginase-mediated T-cell arginine starvation. Compared with bone marrow controls, arginase expression was 20-fold higher in MDSCs but 350-fold higher in MDSCs cultured in IL-13. Recent data have shown increased arginase activity in the plasma of patients with renal cell cancer \[[@CR24]\]. Demonstration that this was being released from CD14^−^ CD11b^+^ or CD66b^+^ MDSCs came from the finding of lower arginase protein activity and expression in patient MDSCs compared with autologous polymorphonuclear cells or control granulocytes, but higher arginase I mRNA expression in patient MDSCs. Furthermore, there was evidence of degranulation of arginase storage granules.

In conclusion, we have demonstrated a significant increase in circulating MDSC levels in pancreatic, esophageal and gastric cancer patients, which is correlated with elevated Treg numbers and associated with an increased expression of arginase I. Importantly, we developed a multivariable model, which has demonstrated that MDSC percentages are a strong independent prognostic factor in these tumor types. We have confirmed the Th2 cytokine skewing previously reported in pancreatic cancer and have extended these observations to esophageal and gastric cancer. Critically, we have also demonstrated significant elevations of the important Th2 cytokine IL-13. These data not only add to our understanding of the immunobiology of these diseases but also may be of importance in informing studies incorporating MDSC inhibition strategies \[[@CR25]\] and IL-13-directed therapies \[[@CR26]\].
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